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Aims Treatment of patients with heart failure (HF) relies on measurement of LVEF. However, the extent to which EF is
recorded varies markedly. We sought to characterize the patient group that is missing a measure of EF, and to
explore the association between missing EF and outcome.
Methods
and results
Individual data on 30 445 patients from 28 observational studies in the Meta-Analysis Global Group in Chronic Heart
Failure (MAGGIC) project were used to compare the prevalence of co-morbidities and outcome across three groups
of HF patients: those with missing EF (HF-mEF), reduced EF (HF-REF), and preserved EF (HF-PEF). A total of 29% had
HF-mEF, 52% HF-REF, and 19% HF-PEF. Compared with patients in whom EF was known, patients with HF-mEF were
older, had a greater prevalence of COPD and previous stroke, and were smokers. Patients with HF-mEF were less
likely to receive evidence-based treatment than those with HF-REF. Adjusted mortality in HF-mEF was similar to that
in HF-REF and greater than that in HF-PEF at 3 years [HF-REF, hazard ratio (HR) 1.03, 95% conﬁdence interval (CI)
0.95–1.12); HF-PEF, HR 0.78, 95% CI 0.71–0.86].
Conclusion Missing EF is common. The short- and long-term outcome of patients with HF-mEF is poor and they exhibit different co-
morbidity proﬁles and treatmentpatterns comparedwithpatientswith knownEF.HFpatientswithmissingEF represent a
high risk group.
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Introduction
Left ventricular ejection fraction has a fundamental role in the man-
agement of patients with heart failure (HF). EF is used to deﬁne
patients with either reduced or preserved EF HF (HF-REF and
HF-PEF, respectively), to guide management with evidence-based
pharmacotherapy and device-based therapies, and to assess
prognosis.1 However in clinical practice, the extent to which EF is
recorded varies markedly. A recent literature-based meta-analysis
of HF studies that did not have an EF entry criterion found that EF
was missing in 0–70% of patients in individual studies.2 Lacking
knowledge of EF implies that the evidence-based HF guidelines
cannot be applied to individual patients with HF.1
The Meta-Analysis Global Group in Chronic heart failure
(MAGGIC) observed that, across 31 individual studies, patients
with HF-PEF have a lower risk of death over 3 years compared
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with those with HF-REF, irrespective of gender, age, ischaemic aeti-
ology, history of hypertension, diabetes, and AF [hazard ratio (HR)
0.68, 95% conﬁdence interval (CI) 0.64–0.71].3 This is in contrast
to some previous studies which have reported no difference in
outcome between patients with HF-PEF and HF-REF.4,5 One poten-
tial explanation for such observations would be the exclusion from
studies comparing outcome in HF-REF with HF-PEF of substantial
numbersof patientsmissing ameasurementof EF, creating an import-
ant sourceof bias. In this context, at leastone study suggested that the
prognosis of patients with HF for whom EF is not recorded is at least
as bad as for those with HF-REF.6
As theMAGGIC cohort includes patients with known andmissing
EF, the aim of this study was to compare the clinical characteristics,
treatment, and health outcomes in HF patients according to
whether EF was known or missing. We hypothesized that patients
missing a measurement of EF may have clinical characteristics that
differ from those for whom EF is recorded.We sought to character-
ize the patient group that is missing a measure of EF, and to explore
the association between missing EF and outcome.
Methods
Themethods for study selection and data extraction for theMAGGIC in-
dividual patient data meta-analysis have been described previously.3We
identiﬁed 56 potentially eligible studies (95 612 patients) that included
patients with HF where EF was not a study entry criterion and which
reported all-cause mortality. We pooled individual patient data from
31 studies [3 pharmacotherapy randomized controlled trials (RCTs), 4
management intervention RCTs, and 24 observational studies] on a pre-
deﬁned set of variables including demographics, medical history, medical
treatment, symptom status, clinical and laboratory variables, follow-up
duration, and deaths. Patients were classiﬁed into one of three groups:
HF-REF, HF-PEF, or missing EF (HF-mEF). Preserved EF was deﬁned as
EF ≥ 50%, measured by echocardiography, angiography, or single
photon emission computed tomography. Reduced EF was therefore
deﬁned as EF,50%. Missing EF was deﬁned when there was no quanti-
tative or qualitative record of EF. No information was available on the
reason for missing EF.
Reasons for missing data will be inﬂuenced by individual study design.
RCTs contributedhalfof thepatientswithHF-REFand43%of thepatients
withHF-PEF to theMAGGICdata set. Consistentwith trial designswhere
EF was a mandatory measurement, few individual patients within these
RCTs were without a recorded measurement of EF (n ¼ 251, 1% of all
RCT participants). To reduce the inﬂuence of obligatory collection of
study-speciﬁc data, RCTs (three trials, 20 536 patients) were therefore
excluded from this current analysis. Patients were further excluded if
aged ,18 years, if death occurred during the index admission, if there
were irresolvable dates, or ifHFwasof valvularor hypertrophic aetiology.
All patients were alive and out of hospital for this analysis.
The proportion of data missing per variable is the proportion of
patients’ missing data in the studies that measured that variable. The
amount of missing covariate data differed between cohorts in whom EF
was known or missing. Using standard multivariable analyses, patients
missing any one of the covariates in the model would be excluded,
biasing a standard complete case analysis towards the EF groups with
more complete data. Thus, standard multivariable analyses could not
be used to assess the association between each variable and HF-mEF.
For comparison of the proportion of co-morbidities and other factors
between patients with and without a measure of EF, formal tests for
statistical signiﬁcance were not performed as the effect of a large
sample size would dominate any useful interpretation of signiﬁcance. In
other words, small differences of questionable clinical signiﬁcance
could be statistically signiﬁcant because of the very large sample size.
To understand the association ofmissing EFwith death fromany cause
at intervals up to 3 years, Cox proportional hazard models were devel-
oped comparing the three EF groups. Models were adjusted for age,
gender, ischaemic aetiology, AF, diabetes, and hypertension, and strati-
ﬁed by study. These covariates are the same as those selected in the
primary analysis of the MAGGIC data set and were available in .90%
of subjects. Year of assessment was not consistently available so could
not be included.Cumulativemortality curveswere produced frommulti-
variable Cox models that were not stratiﬁed by study. Unadjusted mor-
tality per1000person-yearswas also assessed.Analyseswereperformed
using R version 2.12.0.7
Results
Patients included in the study population, and those excluded from
the analysis, are shown in Figure 1. After exclusion of studies as
above, the current analysis involves 30 455 patients from28observa-
tional studies (including four management strategy trials), of whom
29% had HF-mEF, 52% had HF-REF, and 19% had HF-PEF.
A summary of the individual studies is shown in the Supplementary
material, Table S1.
Patient clinical characteristics
Compared with patients with known EF, patients with HF-mEF were
older [71 years (SD 13) vs. 68 years (SD 13)], a greater proportion
had a concomitant diagnosis of COPD (25% vs. 13%) or previous
stroke (13% vs. 10%), orwere smokers (36% vs. 32%). A greater pro-
portion of the HF-mEF group experienced pulmonary oedema than
patientswith known EF (69% vs. 53%) although informationwas only
available in six studies representing 1821 patients. Compared with
those with known EF, symptoms of peripheral oedema, orthopnoea,
paroxysmal nocturnal dyspnoea, shortnessof breath at rest, and rales
on examination were less frequently reported in patients with
HF-mEF (Table 1), who were less likely to be prescribed beta-
blockers (23% vs. 36%) but more likely to be prescribed digoxin
(44% vs. 39%). The HF-mEF group had several demographic charac-
teristics that were intermediate to the HF-REF and HF-PEF groups,
including the proportion of men, history of hypertension, prior myo-
cardial infarction, LBBB, and theproportionof patients receivingACE
inhibitors or ARBs (Table 1).
To investigate the relative association between missing EF meas-
urement and older age and/or co-morbidity, the proportion with
each co-morbidity was assessed among patients aged under 75
years and in those 75 years and above (Table 2). Among patients
aged ≥ 75 years, patients with HF-mEF still had greater proportions
of COPD, previous stroke, pulmonary oedema, or digoxin use than
those with HF-REF or HF-PEF. For example, among patients ≥ 75
years, COPD was present in 26% of HF-mEF patients compared
with 12% of HF-REF patients and 14% of HF-PEF patients.
However, prevalence of current smoking was similar in HF-mEF
and HF-REF, and higher than in HF-PEF, irrespective of age group.
Patients with HF-mEF still had the lowest prevalence of beta-blocker
prescription and symptoms, except for peripheral oedema (36%
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HF-mEF vs. 34% HF-REF vs. 37% HF-PEF). The factors in which
HF-mEF were intermediate to HF-REF and HF-PEF in the whole
group were also intermediate in patients aged ≥ 75 years.
In patients aged ,75 years, proportions of COPD, smoking, pul-
monary oedema, and digoxin use were still highest in those with
HF-mEF compared with those with HF-REF or HF-PEF. However,
in contrast to those aged ≥ 75 years, they had a similar proportion
of previous stroke to thosewithHF-REF. The remaining relationships
between the prevalence of co-morbidities and EF groupsweremain-
tained in patients aged,75 years, except that patients with HF-mEF
had a similar history of hypertension to patients with HF-REF (com-
pared with an intermediate amount in patients aged ≥ 75 years).
Sixty-two per cent of HF-mEF patients were hospitalized at the
time of study enrolment, compared with 46% of those with
HF-REF and 63% of those with HF-PEF. Compared with patients
assessed in an outpatient setting, hospitalized patients were older
(71 vs. 66 years), and a greater proportion were women (46% vs.
28%). While the proportion of HF-mEF in each year of study enrol-
ment was variable, there was no evidence of any temporal trend in
this context (data not shown).
Outcome
Among patientswithHF-mEF, median duration of follow-upwas 116
days [interquartile range (IQR) 85–365days]with 199 (95%CI 188–
211) deaths per 1000 patient-years. In patients with known EF,
median follow-up was 365 days (IQR 102–1346 days) with 156
(95% CI 151–160) deaths per 1000 patient-years. In HF-REF, there
were 159 (95% CI 154–165) deaths per 1000 patient-years and in
HF-PEF, 146 (95% CI 138–154) deaths per 1000 patient-years
(Table 3A).
Unadjusted mortality among patients with HF-mEF was higher
than for patients with HF-REF or HF-PEF from 6 months to 3 years
(Table 3A). After adjustment for age, gender, AF, ischaemic aetiology,
and a historyof hypertension,mortality among patientswithHF-mEF
was similar to that of patients with HF-REF and greater than that of
patients with HF-PEF at each time point up to 3 years (HF-REF, HR
1.03, 95% CI 0.95–1.12; HF-PEF, HR 0.78, 95% CI 0.71–0.86;
Table 3B, Figure 2). The apparent lowearlyHF-mEFmortality is attrib-
uted to one largemulticentre study8 andmay be reﬂective of a differ-
ence in inclusion criteria and recruitment as opposed to a true
difference in HF patients. When this study was removed from the
Figure1 Flowchart of studies in themeta-analysis. HF-mEF heart failure patients withmissing EF; HF-PEF, heart failure patients with preserved EF;
HF-REF, heart failure patients with reduced EF; RCT, randomized controlled trial.
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Table 1 Summary statistics by ejection fraction group (n 5 30455)
Studies, n EF available EF missing
All HF-REF HF-PEF HF-mEF
n (%) 28 21 687 (71) 15 742 (52) 5945 (19) 8768 (29)
Medical history
Age, years 28 68 (13) 67 (13) 72 (12) 71 (13)
.75 years 33 29 44 43
Gender, male 28 65 71 48 56
Hypertension 25 42 38 53 40
Diabetes 27 22 21 24 21
Ischaemic aetiology 27 46 49 36 49
Prior MI 23 36 42 22 31
PAD 12 10 11 8 10
Stroke 18 10 9 12 13
COPD 18 13 12 14 25
Current smoker 23 32 35 22 36
Patient assessment
Pulmonary oedema 6 53 52 55 69
Oedema 18 26 24 32 22
Orthopnoea 12 22 18 44 8
PND 10 21 21 21 13
Rales 16 43 40 50 31
SOBAR 11 33 29 47 7
SOBOE 11 70 73 58 72
Clinical
AF 26 24 22 29 23
LBBB 16 23 28 8 20
NYHA, I/II/III/IV 23 15/49/27/9 14/49/29/8 21/48/22/9 20/48/24/8
CTR 6 56 (8) 57 (8) 54 (8) 56 (7)
HR, b.p.m. 21 82 (22) 82 (21) 82 (24) 79 (17)
SBP, mmHg 20 132 (26) 129 (24) 143 (28) 135 (24)
BMI 12 26.7 (4.9) 26.4 (4.6) 27.5 (5.5) 26.5 (4.7)
≤22.5 kg/m2 17 18 18 17
22.5–30 kg/m2 62 63 56 65
≥30 kg/m2 21 19 28 18
Laboratory values
eGFR 23 61 (25) 61 (25) 61 (26) 58 (25)
Sodium 21 139 (4) 139 (4) 139 (4) 139 (5)
Potassium 12 4.3 (0.6) 4.3 (0.6) 4.2 (0.6) 4.3 (0.6)
Hb 18 130 (21) 132 (20) 126 (22) 127 (23)
Medications
ACE inhibitor or ARB 27 72 78 55 64
Beta-blocker 26 36 37 33 23
Digoxin 27 39 42 29 44
Diuretic 27 81 81 79 83
Spironolactone 18 24 27 17 17
Follow-up
Days to follow-up, median (IQR) 28 365 (102–1346) 365 (109–1270) 478 (94–1512) 116 (85–365)
Died during follow-up 28 29 28 32 16
Continuous data are presented as mean (standard deviation) and categorical data are presented as a percentage, unless otherwise stated.
BMI, body mass index; CTR, cardiothoracic ratio; eGFR, estimated glomerular ﬁltration rate; Hb, haemoglobin; HF-mEF, heart failure patients with missing EF; HF-PEF, heart failure
patients with preserved EF; HF-REF, heart failure patients with reduced EF; HR, heart rate; IQR, interquartile range; MI, myocardial infarction; PAD, peripheral arterial disease; PND,
paroxysmal nocturnal dyspnoea; SBP, systolic blood pressure; SOBAR, shortness of breath at rest; SOBOE, shortness of breath on exertion.
Inﬂuence of missing EF on outcome 1223
analysis, earlymortality in theHF-mEF groupwas not lower than that
of known EF (Supplementary material, Figure S1).
To assess the relevance to assessment of survival of short duration
of follow-up, the analysiswas repeated in studieswith aminimumof 1
year of follow-up (23 studies, n ¼ 12 650, 11% missing EF). Median
follow up was 975 days (IQR 331–1733 days) in HF-mEF and 1208
days (IQR 539–1694 days) in known EF. Adjusted mortality among
patients with HF-mEF remained similar to that in those with
HF-REF up to 1 year, and became greater than HF-REF at 3 years
(HF-REF, HR 0.88, 95% CI 0.79–0.98; HF-PEF, HR 0.69, 95% CI
0.61–0.77).
Adjusted 3 yearmortality among patientswithHF-mEFwas similar
to that of those with HF-REF and higher than that of those with
HF-PEF irrespective of whether the patient was assessed during a
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Table 2 Prevalence of key variables across ejection fraction groups, by age
<75 years ≥75 years
HF-REF HF-PEF HF-mEF HF-REF HF-PEF HF-mEF
n (% of age group) 11182 (58) 3307 (17) 4950 (25) 4537 (41) 2633 (24) 3805 (35)
Most prevalent in whole HF-mEF group, irrespective of age
COPD 397 (12) 188 (15) 70 (23) 293 (12) 219 (14) 159 (26)
Strokea 683 (7) 257 (10) 387 (8) 486 (13) 311 (14) 663 (19)
Current smokera 4082 (41) 788 (27) 2129 (47) 918 (22) 351 (15) 653 (20)
Pulmonary oedema 269 (50) 115 (53) 70 (72) 214 (56) 157 (56) 148 (67)
Digoxin 4067 (46) 688 (31) 2254 (49) 1067 (38) 468 (33) 1425 (42)
Least prevalent in whole HF-mEF group, irrespective of age
Oedemaa 1408 (20) 424 (28) 438 (16) 942 (34) 535 (37) 368 (36)
Orthopnoea 778 (15) 239 (35) 109 (4) 417 (31) 301 (57) 156 (20)
PND 365 (20) 70 (19) 25 (13) 180 (23) 64 (22) 23 (14)
Rales 2049 (34) 623 (46) 582 (22) 1450 (55) 837 (54) 628 (53)
SOBAR 1150 (22) 373 (37) 120 (5) 871 (46) 571 (56) 106 (15)
Beta-blocker 4190 (39) 1180 (36) 1303 (27) 1402 (33) 742 (29) 705 (19)
Intermediate prevalence in whole HF-mEF group, irrespective of age
Gender, male 8528 (76) 1836 (56) 3310 (67) 2636 (58) 1010 (38) 1570 (41)
Hypertensiona 3697 (36) 1590 (52) 1644 (35) 1889 (44) 1371 (55) 1717 (47)
LBBB 1898 (29) 101 (7) 577 (22) 643 (26) 129 (9) 168 (15)
Prior MI 4085 (41) 686 (23) 1567 (34) 1686 (43) 466 (21) 932 (27)
ACE inhibitor or ARB 8825 (81) 1882 (58) 3458 (71) 3075 (70) 1324 (52) 2044 (55)
SBP, mmHg, mean (SD) 127 (23) 141 (27) 132 (23) 135 (26) 147 (30) 141 (26)
n (% of EF and age group that had data on the variable) unless otherwise stated.
HF-mEF, heart failure patients with missing EF; HF-PEF, heart failure patients with preserved EF; HF-REF, heart failure patients with reduced EF; MI, myocardial infarction; PND,
paroxysmal nocturnal dyspnoea; SBP, systolic blood pressure; SOBAR, shortness of breath at rest.
aPrevalence within an age group differs from that in the whole group.
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Table 3 Outcomes
All-cause mortality
30 day 6 month 1 year 3 year
(A) Unadjusted mortality per 1000 patient-years (95% CI)
HF-mEF 175 (144–211) 261 (241–281) 211 (197–225) 199 (188–211)
HF-REF 232 (206–261) 233 (220–246) 190 (182–199) 159 (154–165)
HF-PEF 205 (166–249) 208 (189–229) 171 (159–185) 146 (138–154)
(B) Fully adjusted HR (95% CI), referent ¼ HF-mEF, HR ¼ 1.0
HF-REF 0.85 (0.64–1.12) 1.11 (0.98–1.24) 1.09 (0.99–1.20) 1.03 (0.95–1.12)
HF-PEF 0.57 (0.41–0.80) 0.76 (0.66–0.87) 0.75 (0.66–0.84) 0.78 (0.71–0.86)
Time periods are not exclusive: 30 day ¼ 0–30 days; 6 month ¼ 0–6 months; 1 year ¼ 0–12 months; 3 year ¼ 0–3 years.
CI, conﬁdence interval; HF, heart failure; HR, hazard ratio; HF-mEF, missing EF; HF-PEF, preserved EF; HF-REF, reduced EF.
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hospital admission (HF-REF, HR 1.01, 95%CI 0.91–1.12; HF-PEF, HR
0.78, 95% CI 0.70–0.88); or in an outpatient setting (HF-REF, HR
1.06, 95% CI 0.91–1.23; HF-PEF, HR 0.77, 95% CI 0.65–0.91).
Comparing amount of missingness of
other data across ejection fraction groups
Variables in the MAGGIC data set can be classiﬁed as relating to
medical history, patient assessment, clinical ﬁndings, laboratory
values, andmedication use (Supplementarymaterial, Table S2). Com-
pared with patients in whom EF was known, information was more
often missing in patients with HF-mEF in terms of medical history
(3.5% vs. 1.4%), clinical ﬁndings (39% vs. 21%), and laboratory
values (29% vs. 18%). In contrast, data on factors associated with
patient assessment were less often missing in patients with HF-mEF
(3% vs. 8%). Data on medication use was missing in only a small pro-
portion of both patients with missing and known EF (2.0% vs. 2.3%).
Discussion
The aim of this analysis was systematically to describe and interpret
the extent of missing EF data in observational studies of outcome
for patients with HF. The data from this individual patient
meta-analysis show that, across a spectrum of clinical studies and
registries,missing EFmeasurement is common, occurring in approxi-
mately one in three patients. Compared with patients in whom EF is
known, patientswithHF-mEF are older, and have higher proportions
of non-cardiac co-morbidities and of othermissing variables. Import-
antly, survival in HF-mEF is at least as poor as for patients with
HF-REF. These data highlight the importance of understanding the
group of patients in whom a key variable, such as EF, is missing
when considering outcome in patients with HF.
Outcome
Themainﬁndingof theMAGGICmeta-analysiswasthat reducedEF is
a major determinant of mortality in patients with HF.3 In addition,
older age, male gender, ischaemic aetiology, diabetes, and AF were
strongly associated with increased risk of death from any cause.
Several previous comparisons of survival between patients with
HF-REF and HF-PEF have been reported, with inconsistent results.
One potential source of bias in previous reports was the exclusion
of up to 70% of patients from analyses of outcome due to missing
EF data.4 The current analysis highlights the relevance of exclusion
of patients forwhomEF is not recorded to the assessment of survival
in patients with HF. In our large population, adjusted survival for
patients with HF-mEF was similar to that of patients with HF-REF,
and considerably worse than for those with HF-PEF. In terms of clin-
ical characteristics, comparedwithHF-REF, patientswithHF-mEFare
slightly older (71 vs. 67 years), but have much lower prevalence of
male gender (56% vs. 71%) and similar prevalence of AF, ischaemic
aetiology, and diabetes mellitus. Based on the available data, our
observations suggest that the high risk of death for patients with
HF-mEF is not simply due to a greater prevalence of these clinical
markers of adverse prognosis.
Current recommendations for evidence-based pharmacotherapy
for patients with HF generally apply for patients with low EF.1 Con-
sistent with these management guidelines, patients with HF-PEF in
the MAGGIC meta-analysis were less commonly receiving these
medications than patients with HF-REF.3 In the current analysis, pre-
scription of several evidence-based pharmacological therapies was
less frequent in patients with HF-mEF than in patients with known
EF,most clearly beta-blockade.Major co-morbiditiesmay contribute
to the difference inmedication use across these patient groups and, if
dataonEFarenot available, it is understandable that treating clinicians
may be reluctant to prescribe evidence-based medications. In this
context, the high prevalence of COPD among patients for whom
EF is missing may contribute both to the lack of information on EF
and to the high mortality in these patients. However, an analysis of
patients without COPD showed that mortality among patients
with HF-mEF remained comparable with that of patients with
HF-REF (data not shown). There were insufﬁcient data on other
important conditions such as renal disease, cancer, and indicators
of general frailty to be able to determine the inﬂuence of these
conditions.
Reasons for missing ejection fraction data
As missing EF is an independent marker of adverse outcome, it is im-
portant to consider why EF data might not be available. EF may be
missing because of co-morbidities which present difﬁculties with
obtaining images (e.g. frailty) or difﬁculties in image acquisition (e.g.
tachyarrhythmias suchasAF).However,wecannotdrawconclusions
from our analysis about how patient-related factors may have
affected EF missingness. EF may also be missing for reasons that are
unrelated to either the patient or the usual standard of care, such
as equipment failure or lack of test availability. Alternatively, EF may
be said tobe ‘missing at random’, a somewhatmisleading term,occur-
ring when EF is not measured because of observable, patient-related
factors.9
The presence of major co-morbidities, especially in older, more
frail patients, may inﬂuence the decision-making of clinicians about
investigations such as echocardiography to assess patients with HF.
As already discussed, it is of note that COPD, associated with a
lower likelihood of accurate assessment of EF, was more prevalent
Figure2 Mortality for patientswith heart failurewith reduced EF
(HF-REF), heart failure with preserved EF (HF-PEF), and heart
failurewithmissing EF (HF-mEF), adjusted for age, gender, aetiology
of heart failure, hypertension, diabetes, and AF.
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in patients with HF-mEF. While body habitus will also inﬂuence the
accuracy of EF assessment, it is interesting that the HF-mEF group
did not have a greater proportion of either underweight or obese
patients. Over 40% of patients with HF-mEF were aged 75 years or
more, and these patients had a greater prevalence of prior stroke
than patients with known EF, a difference not evident below 75
years. This suggests that disability amongst older people, from
stroke for example, may inﬂuence measurement of EF. These obser-
vations suggest that the absenceof informationon EFmay be through
these, and potentially additional, uncaptured co-morbidities rather
than with age alone. A previous study, however, did not report
major differences in medical history between those with missing
and known EF.10
Information on EF may have been missing if not required for the
original study, not entered into the study or hospital database, or
notmeasured in the patient. Echo availability, and the extent of infor-
mation obtained, may be inﬂuenced by the physician specialty. For
example, a patient under the care of cardiology services may have
better access to echocardiography than one from general medicine
or older person’s health.11,12 Compounding this, older people with
multiple medical problems are also more likely to be managed
within an older person’s health specialty, medical wards, or in
primary care, whereas younger people with HF may be assessed
andmanaged in cardiology services.12 Evenwhenan echo is obtained,
the reportmaynot quantify EF. In a surveyof primary carepractices in
15 countries, an echo was performed in 82% of patients, but EF was
quantiﬁed in only 39% of these.13 Physician-related factors are also
likely to inﬂuence the absence of information on EF. Clinicians,
other than cardiologists, caring for people with HF, may be less
likely to request, or fully interpret, investigations such as echocardi-
ography. As with patient-related reasons for the absence of informa-
tion on EF, this is likely to inﬂuence the prescription of
evidence-based therapies in a proportion of cases.
Compared with those with known EF, patients with HF-mEF also
had greater proportions of missing covariate data. For all groups of
variables except patient assessment, fewer data were available for
patients with HF-mEF than for those with known EF. Missing data
are not uncommon in observational studies. However, just as bias
can be introduced into a mortality analysis when patients are
missing ameasureof EF, so toocanmissing data impact ondescriptive
statistics if there is a disproportionate amount of missing data
between the groups of interest. For example, the HF-mEF group
had the greatest amountofmissingdata regarding systolic bloodpres-
sure, the average value of whichwas intermediate to that for patients
with HF-REF and HF-PEF. If all of those missing data actually had high
blood pressure, systolic blood pressure in the HF-mEF group would
increase and be closer to that for theHF-PEF group. Conversely, if all
patientsmissing data had lowblood pressure, systolic blood pressure
would be closer to the lower average of the HF-REF group. Multiple
imputation may be suitable to address this problem.
Limitations
As with any meta-analysis, the priorities for data collection in the in-
dividual contributing studiesmaydiffer fromthatof themeta-analysis.
The descriptive statistics and summaries of missing data in this study
arebasedon the amount of data that should be available for each vari-
able, and therefore are dependent on the studies eligible for inclusion
in the main MAGGIC meta-analysis. Studies were included in
MAGGIC after a thorough literature search and direct communica-
tion with investigators, and we were unable to include studies for
which we were unable to obtain patient-level data. Notwithstanding
this point, MAGGIC3 represents themost thoroughmeta-analysis of
outcomes for patientswithHFwith preservedor reduced EF, and the
current report represents the largest assessment of the extent, and
relevance to outcome, of missing EF.
It may be argued that missing EF is a marker for greater co-
morbidity. While age was slightly higher and COPD and smoking
more prevalent in patients with HF-mEF compared with those in
whom EF was recorded, there was no evidence for greater preva-
lence of other co-morbidities known to impact adversely on
outcome for patients with HF, such as diabetes, AF, ischaemic aeti-
ology, or male gender.3 It could be suggested that missing EF may
be a marker for the absence of LV systolic dysfunction. Such a state-
ment is speculative and not possible to sustain in the absence of ob-
jective assessment of cardiac structure and function.
The proportion of patients with HF-PEF in this study is lower than
reported in some community-based studies of HF.14 The MAGGIC
meta-analysis included patients recruited in and out of hospital, but
otherwise there is no readily identiﬁable explanation for this differ-
ence. While selection bias is one possible explanation, this factor is
relevant to the vast majority of studies in HF, including previous
community-based studies.4,14
In this study, HF-mEF was deﬁned when an assessment of EF was
missing from the individual study data sets. While it is possible that
assessment of EFwas delayed for some patients, i.e. after the baseline
study assessment, meaning it would be available for subsequent clin-
ical management decisions, we cannot assess this in the current data
set. The duration of follow-up in the HF-mEF group was relatively
short, with up to 1 year of follow-up available in three-quarters of
the cohort. However, a substantial number of patients with
HF-mEF (n ¼ 2208) were represented in the remaining 25% of the
cohort with longer follow-up and it was still relevant to consider
outcome up to 3 years.
Conclusion
Missing EF is common in observational studies of patientswith a diag-
nosis ofHF. PatientswithHF-mEFexhibit different co-morbidity pro-
ﬁles and treatment patterns compared with patients with known EF,
and the short- and long-termoutcomeof patients is poor.Given their
poor outcome, greater co-morbidities, and variable use of evidence-
based treatments, simply excluding these patients from clinical
studies may result in errant assessment of outcome in patients
with HF.
Supplementary material
Supplementarymaterial is available atEuropean Journal ofHeart Failure
online.
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